

BQ.01.2017

BEYOND USE DATE (BUD) studies provide crucial information on the quality and durability of compounded preparations.

This quarterly only releases the newest results of our BUD studies conducted in collaboration with renowned institutions:

- Hospital for Sick Children
- University of British Columbia
- University of Montreal
- University of Colorado
- University of Connecticut
- University of Western Sydney

Unique Features and Benefits of our BUD Studies:

- Utilize **stability-indicating** methods
- Use **dye-free** vehicles and target 90 days
- Provide stability data in **plastic syringes, and plastic and glass bottles**
- Test both forms of API: **commercial drug and pure powder**
- Perform stability testing at different temperatures (between 4°C and 25°C)
- Involve commonly and uncommonly compounded actives
- Are published in peer-reviewed journals:
 - Canadian Journal of Hospital Pharmacy (CJHP)
 - International Journal of Pharmaceutical Compounding (IJPC)
 - Journal of Pharmacy Practice and Research (JPPR)
 - PLOS ONE

Accurate results ensure that a medication has maintained its compounded dosage.

Did you know? The results of our studies led to the implementation of MEDISCA's **DYE-FREE** oral vehicles at many healthcare establishments!

Extended BUD Stability Studies



ACETAZOLAMIDE 25 mg/mL	ORAL MIX			
	COMMERCIAL DRUG		PURE POWDER	
	5°C	25°C	5°C	25°C
Amber PET Bottle	90 days	90 days	90 days	90 days
PreciseDose™ Dispenser (Clear Syringe)	90 days	90 days	90 days	90 days



ACETAZOLAMIDE 25 mg/mL	ORAL MIX SF			
	COMMERCIAL DRUG		PURE POWDER	
	5°C	25°C	5°C	25°C
Amber PET Bottle	90 days	90 days	90 days	90 days
PreciseDose™ Dispenser (Clear Syringe)	90 days	90 days	90 days	90 days

Less than 10 % loss at 95 % confidence interval.

*Publication pending in Journal of Pediatric Pharmacology and Therapeutics (JPPT)



DAPSONE 2 mg/mL	ORAL MIX		ORAL MIX SF	
	COMMERCIAL DRUG			
	5°C	25°C	5°C	25°C
Amber PET Bottle	90 days	N/A	90 days	90 days
PreciseDose™ Dispenser (Amber Syringe)	90 days	N/A	90 days	90 days

Less than 10 % loss at 95 % confidence interval

*Publication pending in PLOS ONE

BQ.01.2017



HYDROXYCHLOROQUINE SULFATE 25 mg/mL	ORAL MIX		ORAL MIX SF	
	COMMERCIAL DRUG			
	4°C	21°C	4°C	21°C
Amber PET Bottle	90 days	90 days	90 days	90 days
PreciseDose™ Dispenser (Amber Syringe)	90 days	90 days	90 days	90 days

Less than 10 % loss at 95 % confidence interval.

*Publication pending in International Journal of Pharmaceutical Compounding (IJPC)



METRONIDAZOLE 50 mg/mL	ORAL MIX			
	COMMERCIAL DRUG		PURE POWDER	
	4°C	25°C	4°C	25°C
Amber PET Bottle	90 days	90 days	90 days	90 days
PreciseDose™ Dispenser (Amber Syringe)	90 days	90 days	N/A	N/A



METRONIDAZOLE 50 mg/mL	ORAL MIX SF			
	COMMERCIAL DRUG		PURE POWDER	
	4°C	25°C	4°C	25°C
Amber PET Bottle	90 days	90 days	90 days	90 days
PreciseDose™ Dispenser (Amber Syringe)	90 days	90 days	90 days	90 days

Less than 10 % loss at 95 % confidence interval.

*Pending publication in American Journal of Health-System Pharmacy (AJHP)



VANCOMYCIN 50 mg/mL	ORAL SYRUP			
	COMMERCIAL DRUG: INJECTABLE		PURE POWDER	
	4°C	25°C	4°C	25°C
Amber PET Bottle	90 days	36 days	N/A	N/A
PreciseDose™ Dispenser (Amber Syringe)	90 days	30 days	N/A	N/A

Less than 10 % loss at 95 % confidence interval.

*Pending publication in Canadian Journal of Hospital Pharmacy (CJHP)



Over 25
Oral Base Stability Studies
Completed

